When was ARTMS founded?

ARTMS was founded in 2013 and raised its 1st funding round 4 years after it was founded.

Where is ARTMS located?

ARTMS is headquartered in Vancouver, Canada.

How many employees does ARTMS have?

As of Jul 01, 2024, the latest employee count at ARTMS is 24.

Is ARTMS a funded company?

ARTMS is a funded company, having raised a total of $26.6M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2017.

When was the latest funding round of ARTMS?

ARTMS's latest funding was a $***** Grant (prize money) round on Feb 24, 2021, with participation from 1 investor.

Where does ARTMS rank among its competitors?

ARTMS ranks 2nd amongst 27 active competitors, of which 6 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was ARTMS, which secured $300K in Feb, 2021.

Who are the top competitors of ARTMS?

ARTMS's top competitors include NorthStar Medical Radioisotopes, Curium and Alsachim. Among them, ARTMS secured the most recent funding round in February, 2021.

ARTMS - 2026 Company Profile, Team, Funding & Competitors

ARTMS is an acquired company based in Vancouver (Canada), founded in 2013. It operates as a Provider and developer of radioisotope technologies. ARTMS has raised $26.6M in funding from Deerfield and Quark Venture. The company has 27 active competitors, including 6 funded and 4 that have exited. Its top competitors include companies like NorthStar Medical Radioisotopes, Curium and Alsachim.

Company Details

ARTMS is a developer of radioisotope technologies. The company offers technological services to enable the development of radioisotope technologies. The flagship product QIS enables turnkey production of purified radiometals by radioisotope material developers.

Website: artms.ca
Social
Email ID: *****@artms.ca
Phone Number: +1 **********

Key Metrics

Founded Year

2013

Location

Vancouver, Canada

Stage

Acquired

Total Funding

$26.6M in 5 rounds

Latest Funding Round

Grant (prize money), Feb 24, 2021, $*****

Investors

Deerfield & 4 more

Ranked

2^nd among 27 active competitors

Employee Count

24 as on Jul 01, 2024

Similar Companies

NorthStar Medical Radioisotopes & 30 more

Exit Details

Acquired by Telix Pharma (Mar 05, 2024)

View ARTMS's full profile

ARTMS got acquired by Telix Pharma on Mar 05, 2024.

Click here to take a look at ARTMS's acquisition in detail

ARTMS has raised a total funding of $26.6M over 5 rounds. Its first funding round was on 2017. Its latest funding round was a Grant (prize money) round on Feb 24, 2021 for $*****. 1 investor participated in its latest round. ARTMS has 5 institutional investors.

Here is the list of recent funding rounds of ARTMS:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 24, 2021	4560433	Grant (prize money)	2257083	1771148	9298618	4911952
May 13, 2020	1532758	Series A	2928519	8830369	9790823	Quark Venture & 1 more
Aug 14, 2019	6753014	Series A	3708525	2589568	9308160	Canadian Space Agency

Access funding benchmarks and valuations. Sign up today!

View details of ARTMS's funding rounds and investors

ARTMS's employee count trend

ARTMS has 24 employees as of Jul 24. Here is ARTMS's employee count trend over the years:

Uncover ARTMS's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ARTMS include NorthStar Medical Radioisotopes, Curium and Alsachim. Here is the list of Top 10 competitors of ARTMS, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	NorthStar Medical Radioisotopes 2006, Madison (United States), Series B	Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market	$15.1M	Hendricks Holding, Stateline Angels & 4 others	57/100
2nd	ARTMS 2013, Vancouver (Canada), Acquired	Provider and developer of radioisotope technologies	$26.6M	Deerfield, GF Securities & 3 others	57/100
3rd	Curium 2017, Paris (France), Seed	Specialty developer, manufacturer & distributor of radiopharmaceuticals	-	CapVest	56/100
4th	Alsachim 2005, Illkirch Graffenstaden (France), Acquired	Custom synthesis of stable radioisotopes & analytical services for pharmaceutical and biotech companies	-	Naxicap	42/100
5th	AZI 2017, Bunker Hill (United States), Series C	Developer of radiopharmaceuticals for imaging purposes	$58.3M	-	42/100
6th	ATOMIC ALCHEMY 2017, Idaho Falls (United States), Acquired	Limited information available	$150K	Y Combinator, Hemisphere Ventures	39/100
7th	Cassia 2005, San Diego (United States), Unfunded	Isotope labelling services for biomolecules	-	-	37/100
8th	Ground Fluor Pharmaceuticals 2012, Lincoln (United States), Series A	Biomedical company developing proprietary new chemistry for the synthesis of pharmaceutical compounds	-	Nebraska, America’s Seed Fund & 2 others	37/100
9th	CellBion 2010, Seoul (South Korea), Public	Radioactive probes for imaging	-	M Venture Investment, BNH INVESTMENT & 2 others	33/100
10th	Am Chemicals 2003, Oceanside (United States), Unfunded	Oligonucleotide synthesis solutions: solid supports, reagents, and expert services	-	-	33/100